Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.
about
Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonismHemispheric differences in the mesostriatal dopaminergic systemCurrent approaches to enhance glutamate transporter function and expressionEvolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's diseaseDopaminergic Contributions to Vocal LearningVocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.A behavioral genetics approach to understanding D1 receptor involvement in phasic dopamine signaling.A highly reproducible rotenone model of Parkinson's diseaseAutomated quantitative gait analysis in animal models of movement disorders.Interplay between FGF2 and BMP controls the self-renewal, dormancy and differentiation of rat neural stem cellsChronic spinal cord electrical stimulation protects against 6-hydroxydopamine lesions.Enhanced GABA Transmission Drives Bradykinesia Following Loss of Dopamine D2 Receptor Signaling.Structural and biochemical abnormalities in the absence of acute deficits in mild primary blast-induced head trauma.Brain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson diseaseQuantitative evaluation of motor function before and after engraftment of dopaminergic neurons in a rat model of Parkinson's diseaseBotulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson's Disease Differently Affects Behavior.Neuroproteomics as a promising tool in Parkinson's disease research.Accreditation of Biosafe Clinical-Grade Human Embryonic Stem Cells According to Chinese Regulations.Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.Proneural transcription factor Atoh1 drives highly efficient differentiation of human pluripotent stem cells into dopaminergic neuronsAlpha-synuclein mutations impair axonal regeneration in models of Parkinson's disease.Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases.Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's diseaseComparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease.Control of the nigrostriatal dopamine neuron activity and motor function by the tail of the ventral tegmental areaGlycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson diseaseRutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease.Cytokine receptor-like factor 1 (CRLF1) protects against 6-hydroxydopamine toxicity independent of the gp130/JAK signaling pathway.Neuroprotective activity of peripherally administered liver growth factor in a rat model of Parkinson's diseasePolysomnographic Features of Sleep Disturbances and REM Sleep Behavior Disorder in the Unilateral 6-OHDA Lesioned Hemiparkinsonian Rat.Phloroglucinol attenuates motor functional deficits in an animal model of Parkinson's disease by enhancing Nrf2 activity.Noradrenaline and Parkinson's disease.JNK Inhibition Protects Dopamine Neurons and Provides Behavioral Improvement in a Rat 6-hydroxydopamine Model of Parkinson's Disease.Modeling falls in Parkinson's disease: Slow gait, freezing episodes and falls in rats with extensive striatal dopamine lossNeuroprotective effect of a new DJ-1-binding compound against neurodegeneration in Parkinson's disease and stroke model ratsImbalanced estrogen metabolism in the brain: possible relevance to the etiology of Parkinson's diseaseImpaired voluntary wheel running behavior in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.Within-session analysis of amphetamine-elicited rotation behavior reveals differences between young adult and middle-aged F344/BN rats with partial unilateral striatal dopamine depletionProgesterone Exerts a Neuromodulatory Effect on Turning Behavior of Hemiparkinsonian Male Rats: Expression of 3 α -Hydroxysteroid Oxidoreductase and Allopregnanolone as Suggestive of GABAA Receptors Involvement.
P2860
Q21090973-5ABAD964-15E3-48DA-B219-D99682E6CAE4Q26862775-53D78807-09CC-4256-A2A7-5B8851A6B686Q26996723-E6697799-CDE6-4CD1-9301-DF2D12DB7B9FQ27350440-8C57D535-B017-43A4-A770-D7C0EB9B88AEQ28604197-A4AFFED9-2DD9-4A34-8CF8-CB126390EACDQ30380046-86D1FA65-6C7C-4FCD-A192-42C3A138E1E4Q30454614-A66A6ABF-642F-4B76-81A5-151CDCCC3D8EQ30474975-85F7441E-C181-4E5A-9A7D-FFB1666C99FFQ30490799-D9A64D25-23A4-4E70-A13A-D425E52DA533Q30496179-6B968862-37A7-45EE-A073-CA4245F59189Q30500268-BE8FB68C-6641-4AD4-861B-F386AD2617DEQ30566773-016982C7-5326-4961-BA84-9003F46E033FQ30762059-50C6B9A4-65A0-4F4C-9901-A7C460DE5A1CQ33645240-B4F0FC42-7E59-4005-8E5E-97D8E82DCD42Q33718730-10116D60-67B6-4A8B-8553-3F637D485AA9Q33728539-5D6A8543-0253-4A63-9CE4-40B26975AA01Q33819387-1D1B3BC9-CEBA-48E3-B4A3-7FAB24E2569AQ33821316-799F4174-BF6F-452D-8519-210112C0EBCCQ33905385-2BBF465B-825B-416F-8FB3-DCF6BAD0FCD7Q33931801-25BCC0E6-5305-4251-BAD7-6791EFCC6DB2Q33975612-1B2D02ED-715B-474B-BE2C-E5B96F38F14EQ34159183-940ED849-8C3D-41FB-A9F9-4E999CE81DEFQ34179881-33B49ECE-D868-4847-A233-6F146A506994Q34224832-B5272D6D-1414-4EB5-A3BE-78EC77696618Q34245009-484F5FED-1FDA-4D67-AFBC-76E5D33016FBQ34356966-FBE76BE7-7226-4B15-A244-4F4472A2503DQ34591684-C457470A-3AC1-40D5-85CC-E017B0A5DB20Q34634606-FB1CABB2-51F8-4F22-AD42-487A7AF63407Q34789499-E242747F-BA7D-4ED9-9D28-853272C087F7Q34826133-5637870A-F209-458F-92C3-DB8E1222BF8AQ34919931-1E7061A1-223E-43D4-B5AB-1109434D6764Q34970674-7D951F58-26F3-4674-A60D-F596F19FE163Q35013240-D1F5E756-9C99-4962-9853-D8036EFF761BQ35031088-9A586B9E-E2BE-4C4F-81D4-9937D8C25148Q35070996-36B4AFA7-477B-4056-83ED-DFF8483BF56BQ35121851-73507E10-1DB5-4EEF-BD69-CD09F0135942Q35124298-9F5CBDC7-B4E8-424F-B0EB-2C2B8F8AFF59Q35133598-F4A3871C-562D-46BC-8103-830387F5E299Q35190293-6C36357F-8369-4B40-A659-5284B136C84DQ35410044-22A5BA59-DB1C-4E09-ADD1-B5DAC475E797
P2860
Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Modeling Parkinson's disease i ...... of the nigrostriatal pathway.
@ast
Modeling Parkinson's disease i ...... of the nigrostriatal pathway.
@en
Modeling Parkinson's disease i ...... of the nigrostriatal pathway.
@nl
type
label
Modeling Parkinson's disease i ...... of the nigrostriatal pathway.
@ast
Modeling Parkinson's disease i ...... of the nigrostriatal pathway.
@en
Modeling Parkinson's disease i ...... of the nigrostriatal pathway.
@nl
prefLabel
Modeling Parkinson's disease i ...... of the nigrostriatal pathway.
@ast
Modeling Parkinson's disease i ...... of the nigrostriatal pathway.
@en
Modeling Parkinson's disease i ...... of the nigrostriatal pathway.
@nl
P2093
P356
P1476
Modeling Parkinson's disease i ...... of the nigrostriatal pathway.
@en
P2093
Arjan Blokland
Jos Prickaerts
Ronald Deumens
P304
P356
10.1006/EXNR.2002.7891
P407
P577
2002-06-01T00:00:00Z